Combination therapy for treating drug-resistance cancer using Rifabutin
The present invention relates to an anticancer adjuvant containing rifabutin as an active ingredient, which is a novel anticancer adjuvant which can be administered in combination with anticancer drugs to resistant cancer cells overexpressing P-glycoprotein (P-gp), which can excrete an anticancer ag...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; kor |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | YOON SUNGPIL KIM HYUNG SIK LEE BYUNG MU PARK JAE HYEON LEE JI SUN PARK JI WON OH YUNMOON |
| description | The present invention relates to an anticancer adjuvant containing rifabutin as an active ingredient, which is a novel anticancer adjuvant which can be administered in combination with anticancer drugs to resistant cancer cells overexpressing P-glycoprotein (P-gp), which can excrete an anticancer agent out of the cell. When using the anticancer adjuvant of the present invention, side effects on normal cells in the human body can be minimized and anticancer drug resistance can be effectively overcome while using a smaller amount compared to conventional drugs, so it can be usefully used in related technologies.
본 발명은 리파부틴(rifabutin)을 유효성분으로 포함하는 항암 보조제에 관한 것으로, 항암제를 세포 밖으로 배출시킬 수 있는 P-gp(P-glycoprotein)가 과발현되어 있는 내성 암세포에 항암제와 함께 병용 투여할 수 있는 새로운 항암 보조제에 관한 것이다. 본 발명의 항암 보조제를 사용하는 경우 인체 내의 정상 세포에 대한 부작용을 최소화할 수 있고, 종래의 약물에 비해 적은 양을 사용하면서도 효과적으로 항암제 내성을 극복할 수 있으므로, 관련 기술에 유용하게 사용될 수 있다. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_KR20230126265A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>KR20230126265A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_KR20230126265A3</originalsourceid><addsrcrecordid>eNrjZHB3zs9NysxLLMnMz1MoyUgtSiyoVEjLL1IoKUoFCualK6QUlabrFqUWZxaXJOYlpyokg8gihdJikGRQZlpiUilQHQ8Da1piTnEqL5TmZlB2cw1x9tBNLciPTy0uSExOzUstifcOMjIwMjYwNDIzMjN1NCZOFQB3nTU_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Combination therapy for treating drug-resistance cancer using Rifabutin</title><source>esp@cenet</source><creator>YOON SUNGPIL ; KIM HYUNG SIK ; LEE BYUNG MU ; PARK JAE HYEON ; LEE JI SUN ; PARK JI WON ; OH YUNMOON</creator><creatorcontrib>YOON SUNGPIL ; KIM HYUNG SIK ; LEE BYUNG MU ; PARK JAE HYEON ; LEE JI SUN ; PARK JI WON ; OH YUNMOON</creatorcontrib><description>The present invention relates to an anticancer adjuvant containing rifabutin as an active ingredient, which is a novel anticancer adjuvant which can be administered in combination with anticancer drugs to resistant cancer cells overexpressing P-glycoprotein (P-gp), which can excrete an anticancer agent out of the cell. When using the anticancer adjuvant of the present invention, side effects on normal cells in the human body can be minimized and anticancer drug resistance can be effectively overcome while using a smaller amount compared to conventional drugs, so it can be usefully used in related technologies.
본 발명은 리파부틴(rifabutin)을 유효성분으로 포함하는 항암 보조제에 관한 것으로, 항암제를 세포 밖으로 배출시킬 수 있는 P-gp(P-glycoprotein)가 과발현되어 있는 내성 암세포에 항암제와 함께 병용 투여할 수 있는 새로운 항암 보조제에 관한 것이다. 본 발명의 항암 보조제를 사용하는 경우 인체 내의 정상 세포에 대한 부작용을 최소화할 수 있고, 종래의 약물에 비해 적은 양을 사용하면서도 효과적으로 항암제 내성을 극복할 수 있으므로, 관련 기술에 유용하게 사용될 수 있다.</description><language>eng ; kor</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230830&DB=EPODOC&CC=KR&NR=20230126265A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230830&DB=EPODOC&CC=KR&NR=20230126265A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>YOON SUNGPIL</creatorcontrib><creatorcontrib>KIM HYUNG SIK</creatorcontrib><creatorcontrib>LEE BYUNG MU</creatorcontrib><creatorcontrib>PARK JAE HYEON</creatorcontrib><creatorcontrib>LEE JI SUN</creatorcontrib><creatorcontrib>PARK JI WON</creatorcontrib><creatorcontrib>OH YUNMOON</creatorcontrib><title>Combination therapy for treating drug-resistance cancer using Rifabutin</title><description>The present invention relates to an anticancer adjuvant containing rifabutin as an active ingredient, which is a novel anticancer adjuvant which can be administered in combination with anticancer drugs to resistant cancer cells overexpressing P-glycoprotein (P-gp), which can excrete an anticancer agent out of the cell. When using the anticancer adjuvant of the present invention, side effects on normal cells in the human body can be minimized and anticancer drug resistance can be effectively overcome while using a smaller amount compared to conventional drugs, so it can be usefully used in related technologies.
본 발명은 리파부틴(rifabutin)을 유효성분으로 포함하는 항암 보조제에 관한 것으로, 항암제를 세포 밖으로 배출시킬 수 있는 P-gp(P-glycoprotein)가 과발현되어 있는 내성 암세포에 항암제와 함께 병용 투여할 수 있는 새로운 항암 보조제에 관한 것이다. 본 발명의 항암 보조제를 사용하는 경우 인체 내의 정상 세포에 대한 부작용을 최소화할 수 있고, 종래의 약물에 비해 적은 양을 사용하면서도 효과적으로 항암제 내성을 극복할 수 있으므로, 관련 기술에 유용하게 사용될 수 있다.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHB3zs9NysxLLMnMz1MoyUgtSiyoVEjLL1IoKUoFCualK6QUlabrFqUWZxaXJOYlpyokg8gihdJikGRQZlpiUilQHQ8Da1piTnEqL5TmZlB2cw1x9tBNLciPTy0uSExOzUstifcOMjIwMjYwNDIzMjN1NCZOFQB3nTU_</recordid><startdate>20230830</startdate><enddate>20230830</enddate><creator>YOON SUNGPIL</creator><creator>KIM HYUNG SIK</creator><creator>LEE BYUNG MU</creator><creator>PARK JAE HYEON</creator><creator>LEE JI SUN</creator><creator>PARK JI WON</creator><creator>OH YUNMOON</creator><scope>EVB</scope></search><sort><creationdate>20230830</creationdate><title>Combination therapy for treating drug-resistance cancer using Rifabutin</title><author>YOON SUNGPIL ; KIM HYUNG SIK ; LEE BYUNG MU ; PARK JAE HYEON ; LEE JI SUN ; PARK JI WON ; OH YUNMOON</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_KR20230126265A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; kor</language><creationdate>2023</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>YOON SUNGPIL</creatorcontrib><creatorcontrib>KIM HYUNG SIK</creatorcontrib><creatorcontrib>LEE BYUNG MU</creatorcontrib><creatorcontrib>PARK JAE HYEON</creatorcontrib><creatorcontrib>LEE JI SUN</creatorcontrib><creatorcontrib>PARK JI WON</creatorcontrib><creatorcontrib>OH YUNMOON</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>YOON SUNGPIL</au><au>KIM HYUNG SIK</au><au>LEE BYUNG MU</au><au>PARK JAE HYEON</au><au>LEE JI SUN</au><au>PARK JI WON</au><au>OH YUNMOON</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Combination therapy for treating drug-resistance cancer using Rifabutin</title><date>2023-08-30</date><risdate>2023</risdate><abstract>The present invention relates to an anticancer adjuvant containing rifabutin as an active ingredient, which is a novel anticancer adjuvant which can be administered in combination with anticancer drugs to resistant cancer cells overexpressing P-glycoprotein (P-gp), which can excrete an anticancer agent out of the cell. When using the anticancer adjuvant of the present invention, side effects on normal cells in the human body can be minimized and anticancer drug resistance can be effectively overcome while using a smaller amount compared to conventional drugs, so it can be usefully used in related technologies.
본 발명은 리파부틴(rifabutin)을 유효성분으로 포함하는 항암 보조제에 관한 것으로, 항암제를 세포 밖으로 배출시킬 수 있는 P-gp(P-glycoprotein)가 과발현되어 있는 내성 암세포에 항암제와 함께 병용 투여할 수 있는 새로운 항암 보조제에 관한 것이다. 본 발명의 항암 보조제를 사용하는 경우 인체 내의 정상 세포에 대한 부작용을 최소화할 수 있고, 종래의 약물에 비해 적은 양을 사용하면서도 효과적으로 항암제 내성을 극복할 수 있으므로, 관련 기술에 유용하게 사용될 수 있다.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; kor |
| recordid | cdi_epo_espacenet_KR20230126265A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Combination therapy for treating drug-resistance cancer using Rifabutin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T08%3A55%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=YOON%20SUNGPIL&rft.date=2023-08-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EKR20230126265A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |